Australia's Acrux rises on hormonal product ownership even after deal termination

Acrux

20/09/2023 06:08

** Shares of Australian speciality pharmaceutical company
Acrux  ACR.AX  rise as much as 4.9% to A$0.043, marking their
biggest intraday pct gain since Sept. 6 
    ** ACR at its highest level since Sept. 12
    ** Says to terminate commercialisation deal of the generic
Testosterone Topical Solution product for the U.S. market
    ** Says post termination co will retain exclusive ownership
of all rights and intellectual property over product
    ** Stock down 41.4% this year, as of last close vs 2.2%
increase in benchmark S&P/ASX 200 index  .AXJO 

 (Reporting by Roshan Thomas in Bengaluru)
 ((Roshan.Thomas@thomsonreuters.com;))